EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| EYPT | EyePoint, Inc. | 2026-04-02 18:15:02 | 13.6 | 0.2 | 1.49 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EYPT | 0001314102 | EyePoint, Inc. | US30233G2093 | 549300QE1RU34T50MR69 | 262774444 | Nasdaq | 3826 | Laboratory Analytical Instruments | 1231 | DE | 480 PLEASANT STREET | WATERTOWN | MA | 02472 | UNITED STATES | US | 617-926-5000 | 480 PLEASANT STREET, WATERTOWN, MA, 02472 | 480 PLEASANT STREET, WATERTOWN, MA, 02472 | EyePoint Pharmaceuticals, Inc. | Pharmaceuticals | — | — | — | http://www.psivida.com | 642,600,000 | 82,826,416 | 83,431,950 | EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery. | 2026-04-02 17:21:54 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 642,600,000 | 191,800,000 | 42.5466 | 83,431,950 | 14,703,190 | 21.3931 |
| 2024 | 450,800,000 | 217,900,000 | 93.5595 | 68,728,760 | 18,897,968 | 37.9243 |
| 2023 | 232,900,000 | 23,389,613 | 11.1639 | 49,830,792 | 15,528,866 | 45.2711 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Ramiro Ribeiro | Chief Medical Officer | 2024 | 404,167 | 60,000 | 0 | 276,359 | 2,052 | 3,533,919 |
| George Elston | Chief Financial Officer, Executive Vice President | 2024 | 507,368 | 0 | 918,000 | 291,917 | 25,189 | 3,204,973 |
| Jay Duker | Chief Executive Officer, President | 2024 | 669,500 | 0 | 1,836,000 | 498,888 | 25,421 | 5,954,807 |
| Nancy Lurker | Chair, Chief Executive Officer, President, Director | 2023 | 570,025 | 49,242 | 1,038,477 | 574,486 | 25,527 | 3,737,385 |
| George Elston | Chief Financial Officer, Executive Vice President | 2023 | 487,824 | 24,938 | 282,912 | 367,141 | 25,441 | 1,780,125 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 214 |
| 2024 | 165 |
| 2023 | 121 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 31,371,000 | 43,273,000 | 46,018,000 |
| Cost Of Revenue | 2,066,000 | 3,712,000 | 4,632,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 221,039,000 | 132,926,000 | 64,662,000 |
| General And Administrative Expenses | 51,610,000 | 52,358,000 | 40,102,000 |
| Operating Expenses | 274,805,000 | 189,127,000 | 121,085,000 |
| Operating Income | -243,434,000 | -145,854,000 | -75,067,000 |
| Net Income | -231,962,000 | -130,870,000 | -70,795,000 |
| Earnings Per Share Basic | -3.17 | -2.32 | -1.82 |
| Earnings Per Share Diluted | -3.17 | -2.32 | -1.82 |
| Weighted Average Shares Outstanding Basic | 73,251 | 56,298 | 38,904,000 |
| Weighted Average Shares Outstanding Diluted | 73,251 | 56,298 | 38,904,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 101,821,000 | 99,704,000 | 281,263,000 |
| Marketable Securities Current | 204,265,000 | 271,209,000 | 49,787,000 |
| Accounts Receivable | 651,000 | 607,000 | 805,000 |
| Inventories | 1,813,000 | 2,305,000 | 3,906,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 1,964,000 | 1,405,000 | 1,009,000 |
| Total Assets Current | 328,655,000 | 383,306,000 | 344,800,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 9,023,000 | 8,177,000 | 5,251,000 |
| Other Assets Non Current | 5,945,000 | 5,832,000 | — |
| Total Assets Non Current | 35,341,000 | 35,159,000 | 10,384,000 |
| Total Assets | 363,996,000 | 418,465,000 | 355,184,000 |
| Accounts Payable | 10,490,000 | 11,721,000 | 6,504,000 |
| Deferred Revenue | 0 | 17,784,000 | 38,592,000 |
| Short Term Debt | — | — | 0 |
| Other Liabilities Current | 2,140,000 | 1,440,000 | 646,000 |
| Total Liabilities Current | 37,024,000 | 49,048,000 | 63,263,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 87,000 | 205,000 | — |
| Total Liabilities Non Current | 20,859,000 | 32,916,000 | 25,598,000 |
| Total Liabilities | 57,883,000 | 81,964,000 | 88,861,000 |
| Common Stock | 83,000 | 68,000 | 49,000 |
| Retained Earnings | -1,104,978,000 | -873,016,000 | -742,146,000 |
| Accumulated Other Comprehensive Income | 961,000 | 1,028,000 | 864,000 |
| Total Shareholders Equity | 306,113,000 | 336,501,000 | 266,323,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 2,309,000 | 1,540,000 | 464,000 |
| Share Based Compensation Expense | 27,873,000 | 36,740,000 | 12,057,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | -492,000 | -1,600,000 | 1,553,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -240,110,000 | -126,226,000 | 1,875,000 |
| Purchases Of Marketable Securities | 252,020,000 | 398,303,000 | 55,116,000 |
| Sales Of Marketable Securities | 323,725,000 | 183,000,000 | 55,284,000 |
| Acquisition Of Property Plant And Equipment | 3,280,000 | 4,052,000 | 3,483,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 68,580,000 | -219,355,000 | -3,315,000 |
| Tax Withholding For Share Based Compensation | 1,388,000 | 4,512,000 | 169,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 173,445,000 | 163,314,000 | 226,174,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | 0 |
| Repayment Of Long Term Debt | — | 0 | 30,000,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 173,647,000 | 164,022,000 | 187,070,000 |
| Change In Cash | 2,117,000 | -181,559,000 | 185,630,000 |
| Cash At End Of Period | 101,821,000 | 99,704,000 | 281,263,000 |
| Income Taxes Paid | 200,000 | — | — |
| Interest Paid | — | 0 | 1,405,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -3.17 | -2.32 | -1.82 |
| Price To Earnings Ratio | -5.7634 | -3.2112 | -12.6978 |
| Earnings Growth Rate | 36.6379 | 27.4725 | -33.5766 |
| Price Earnings To Growth Ratio | -0.1573 | -0.1169 | 0.3782 |
| Book Value Per Share | 4,178.96 | 5,977.1395 | 6.8456 |
| Price To Book Ratio | 0.0044 | 0.0012 | 3.3759 |
| Ebitda | -229,420,000 | -129,316,000 | -69,084,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 3,155,000 | 4,466,000 | 4,355,000 |
| Free Cash Flow | -243,265,000 | -130,692,000 | -2,480,000 |
| Return On Equity | -0.7578 | -0.3889 | -0.2658 |
| One Year Beta | 1.1023 | 1.724 | 1.1028 |
| Three Year Beta | 1.2378 | 1.1336 | 1.1207 |
| Five Year Beta | 1.1742 | 1.2408 | 1.2543 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Duker Jay S. | Director, President and CEO | 2026-03-23 | 76,766 | D | 986 |
| Duker Jay S. | Director, President and CEO | 2026-03-23 | 76,766 | A | 177,431 |
| Duker Jay S. | Director, President and CEO | 2026-03-23 | 52,500 | D | 7,800 |
| Duker Jay S. | Director, President and CEO | 2026-03-23 | 52,500 | A | 52,500 |
| Duker Jay S. | Director, President and CEO | 2026-03-23 | 97,500 | D | 82,500 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 22,833,061 | 1,249,757 | 18.27 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 22,527 | 1,233 | 18.2701 |
| Corient Private Wealth LLC | 2025-12-31 | 2,329,224 | 127,489 | 18.27 |
| Caitong International Asset Management Co., Ltd | 2025-12-31 | 3,069 | 168 | 18.2679 |
| Blue Owl Capital Holdings LP | 2025-12-31 | 7,172,692 | 392,594 | 18.27 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Direxion Shares ETF Trust | 2026-01-31 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | PILL | 15,325 | 207,194 | 1.1554 |
| Global X Funds | 2026-01-31 | Global X Russell 2000 ETF | RSSL | 34,181 | 462,127.12 | 0.0334 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-01-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 80,292 | 1,085,547.84 | 0.0406 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Class P Shares | GSXPX | 11,363 | 153,627.76 | 0.0165 |
| GOLDMAN SACHS TRUST | 2026-01-31 | Class R6 Shares | GTTUX | 11,363 | 153,627.76 | 0.0165 |